EUVIMEDEUVIMED entdecken
Fallbericht

Neoadjuvant PD-1 Inhibitors: A Tale of Two Cases

David Baltazar, Nathalie Zeitouni, Neel Patel, Justin Moser

Journal of Drugs in Dermatology · 2024

DOI: 10.36849/jdd.7043 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Drugs in Dermatology, 2024. Verfasst von David Baltazar und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Skin Neoplasms, Carcinoma, Merkel Cell.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment responses for locally advanced cutaneous squamous cell carcinoma (cSCC) and Merkel cell carcinoma (MCC) are often short lived and are marred with recurrences. The introduction of adjuvant PD-1 inhibitors has demonstrated significant improvement in both, response rates, and duration of response. For patients with high-risk resectable disease, adjuvant treatments have not demonstrated an ability to reduce recurrence risk. However, there is an opportunity in the neoadjuvant setting to alter recurrence risk. Here we dem-onstrate two cases of neoadjuvant treatment of cSCC and MCC with impressive results. J Drugs Dermatol. 2024;23(2): doi:10.36849/JDD.7043e.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Squamous CellSkin NeoplasmsCarcinoma, Merkel CellHumansNeoadjuvant TherapyImmune Checkpoint Inhibitors

Substanzen

Immune Checkpoint Inhibitors

Zitieren

APA

Baltazar, D., Zeitouni, N., Patel, N., & Moser, J. (2024). Neoadjuvant PD-1 Inhibitors: A Tale of Two Cases. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.7043

Vancouver

Baltazar D, Zeitouni N, Patel N, Moser J. Neoadjuvant PD-1 Inhibitors: A Tale of Two Cases. Journal of Drugs in Dermatology. 2024. doi:10.36849/jdd.7043

BibTeX
@article{Baltazar2024,
  author = {Baltazar, David and Zeitouni, Nathalie and Patel, Neel and Moser, Justin},
  title = {Neoadjuvant PD-1 Inhibitors: A Tale of Two Cases},
  journal = {Journal of Drugs in Dermatology},
  year = {2024},
  doi = {10.36849/jdd.7043}
}
Kostenlos starten →